Stockreport

Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One

Adial Pharmaceuticals, Inc  (ADIL) 
US:NASDAQ Investor Relations: adialpharma.com
PDF GLEN ALLEN, Va., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company fo [Read more]